Amgen’s KRAS Inhibitor Registers Long-Lasting Performance in Solid Tumors
By Pavel Ryzhov, Ph.D. Amgen recently announced updated data from the Phase 1 cohort of the CodeBreaK 100 clinical trial [1] that aims to evaluate sotorasib in patients with advanced …
Read More